Lars Hansen
Overview
Explore the profile of Lars Hansen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
170
Citations
4116
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Baird A, Rathod S, Hansen L, Appleby L, Rodway C, Turnbull P
Schizophr Bull
. 2025 Feb;
PMID: 39937218
Background And Hypothesis: Suicide rates among people with schizophrenia and other primary psychotic disorders are high, with the steepest increase in risk in the first years following contact with mental...
2.
Brown T, de la Paz J, Murphy T, Hansen L
Aesthetic Plast Surg
. 2024 Oct;
PMID: 39470820
Recent regulatory changes in Australian cosmetic surgery necessitate preoperative screening for body dysmorphic disorder (BDD). This study, which focuses on patient outcomes, evaluates the COPs tool's efficacy and examines its...
3.
Selvarajah V, Robertson D, Hansen L, Jermutus L, Smith K, Coggi A, et al.
Kidney Int
. 2024 Sep;
106(6):1170-1180.
PMID: 39218393
Cotadutide is a glucagon-like peptide-1 (GLP-1) and glucagon receptor agonist that may improve kidney function in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD). In this phase...
4.
Yu H, Ueckert S, Zhou L, Cheng J, Robertson D, Hansen L, et al.
CPT Pharmacometrics Syst Pharmacol
. 2024 Jul;
13(9):1582-1594.
PMID: 39044369
Cotadutide is a dual glucagon-like peptide-1 (GLP-1)/glucagon receptor agonist. Gastrointestinal adverse effects are known to be associated with GLP-1 receptor agonism and can be mitigated through tolerance development via a...
5.
Pritchard C, Silk A, Hansen L, Panesar H, Berendt T
J Neurol Sci
. 2024 Jun;
462:123094.
PMID: 38897154
Objective: We examine whether the rise in neurological death rates over the 21st century are solely explained by the Gompertzian hypothesis. Study Design: We examine two data-sets. First, Office of...
6.
Golubic R, Kennet J, Parker V, Robertson D, Luo D, Hansen L, et al.
Diabetes Obes Metab
. 2024 Apr;
26(7):2634-2644.
PMID: 38562018
Aims: To establish which components of energy balance mediate the clinically significant weight loss demonstrated with use of cotadutide, a glucagon-like peptide-1 (GLP-1)/glucagon receptor dual agonist, in early-phase studies. Materials...
7.
Parker V, Robertson D, Erazo-Tapia E, Havekes B, Phielix E, de Ligt M, et al.
Nat Metab
. 2023 Dec;
5(12):2086-2093.
PMID: 38066113
Cotadutide is a dual glucagon-like peptide 1 and glucagon receptor agonist under development for the treatment of non-alcoholic steatohepatitis and type 2 diabetes mellitus (T2DM) and chronic kidney disease. Non-alcoholic...
8.
Michelsen C, Jorgensen C, Heltberg M, Jensen M, Lucchetti A, Petersen P, et al.
BMC Anesthesiol
. 2023 Nov;
23(1):391.
PMID: 38030979
Background: Machine-learning models may improve prediction of length of stay (LOS) and morbidity after surgery. However, few studies include fast-track programs, and most rely on administrative coding with limited follow-up...
9.
Asano M, Sekikawa A, Sugeno M, Matsuoka O, Robertson D, Hansen L
Diabetes Obes Metab
. 2023 Jun;
25(8):2290-2299.
PMID: 37337366
Aim: To assess the safety/tolerability, efficacy and pharmacokinetics of once-daily, 600-μg cotadutide in Japanese type 2 diabetes patients with a body mass index of 25 kg/m or higher. Materials And...
10.
Larsen I, Povolo L, Zhou L, Tian W, Mygind K, Hintze J, et al.
Proc Natl Acad Sci U S A
. 2023 May;
120(21):e2302584120.
PMID: 37186866
Mutations in the gene cause structural heart defects and renal anomalies syndrome, but the function of the encoded protein remains unknown. We previously reported wide occurrence of O-mannose glycans on...